Mineralys Therapeutics (MLYS) Stock Price, Quote, News & History

Comments

Mineralys Therapeutics Inc (MLYS) Stock Price, Quote, News & History

MLYSNASDAQ

Trade with Public

$28.77

0.260.91%

At close: Mar 3, 4:00 PM EST

$28.77

0.260.91%

Pre-Market: 7:00 AM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

-

Close

$28.77

Volume / Avg.

0 / 1.25M

Day Range

- - -

52 Wk Range

8.79 - 47.65

Market Cap

$2.28B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.77%

Days to Cover

7.74

Recent Mineralys Therapeutics Inc News

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Avi Kapoor

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-171.37M

Investing Cash Flow (TTM)

-202.69M

Financing Cash Flow (TTM)

494.39M

Free Cash Flow (TTM)

-171.37M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

120.32M

Analyst Trends and Forecast

3

Sep 25

1

Oct 25

2

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.73B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.95

Earnings Yield % (TTM)

-10.14%

Earnings Yield % (FWD)

-7.82%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$7.28

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$217.60M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$28.77

Volume / Avg.

0 / 1.25M

Day Range

- - -

52 Wk Range

8.79 - 47.65

Market Cap

$2.28B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.77%

Days to Cover

7.74

About

Sector

Health Care

Industry

Biotechnology

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administere...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Mineralys Therapeutics (MLYS) stock?

A

You can purchase shares of Mineralys Therapeutics (NASDAQ:MLYS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Mineralys Therapeutics (MLYS) competitors?

A

Other companies in Mineralys Therapeutics’s space includes: Immunome Inc (NASDAQ:IMNM), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Ascentage Pharma Group International (NASDAQ:AAPG), Olema Pharmaceuticals inc (NASDAQ:OLMA) and Dyne Therapeutics Inc (NASDAQ:DYN).

Q

What is the forecast, or price target, for Mineralys Therapeutics (MLYS) stock?

A

Mineralys Therapeutics has a consensus price target of $45.86.

Q

What is the current price for Mineralys Therapeutics (MLYS)?

A

The stock price for Mineralys Therapeutics (NASDAQ: MLYS) is $28.77 last updated March 4, 2026 at 4:00 PM EST.

Q

Does Mineralys Therapeutics (MLYS) pay a dividend?

A

There are no upcoming dividends for Mineralys Therapeutics.

Q

When is Mineralys Therapeutics (NASDAQ:MLYS) reporting earnings?

A

Mineralys Therapeutics does not have any upcoming earnings scheduled.

Q

Is Mineralys Therapeutics (MLYS) going to split?

A

There is no upcoming split for Mineralys Therapeutics.

Q

What sector and industry does Mineralys Therapeutics (MLYS) operate in?

A

Mineralys Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$21.75

-0.23%

Ascentage Pharma Group International

NASDAQ:AAPG

$22.25

%

Olema Pharmaceuticals inc

NASDAQ:OLMA

$24.30

-0.16%

Dyne Therapeutics Inc

NASDAQ:DYN

$15.16

-0.46%

BioCryst Pharmaceuticals Inc

NASDAQ:BCRX

$8.64

0.81%

Stoke Therapeutics Inc

NASDAQ:STOK

$34.01

-1.21%

Dianthus Therapeutics Inc

NASDAQ:DNTH

$61.52

-0.83%

Key Statistics

Open

-

Close

$28.77

Volume / Avg.

0 / 1.25M

Day Range

- - -

52 Wk Range

8.79 - 47.65

Market Cap

$2.28B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.77%

Days to Cover

7.74

Recent Mineralys Therapeutics Inc News

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Avi Kapoor

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-171.37M

Investing Cash Flow (TTM)

-202.69M

Financing Cash Flow (TTM)

494.39M

Free Cash Flow (TTM)

-171.37M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

120.32M

Analyst Trends and Forecast

3

Sep 25

1

Oct 25

2

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.73B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.95

Earnings Yield % (TTM)

-10.14%

Earnings Yield % (FWD)

-7.82%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$7.28

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$217.60M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$28.77

Volume / Avg.

0 / 1.25M

Day Range

- - -

52 Wk Range

8.79 - 47.65

Market Cap

$2.28B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

15.77%

Days to Cover

7.74

About

Sector

Health Care

Industry

Biotechnology

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administere...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry